Pharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Elisabeth Bjork sold 10,000 shares of Pharvaris stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the transaction, the director directly owned 15,167 shares in the company, valued at $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pharvaris Stock Down 2.3%

NASDAQ:PHVS traded down $0.69 during midday trading on Friday, reaching $29.85. The stock had a trading volume of 171,274 shares, compared to its average volume of 226,219. The firm has a fifty day simple moving average of $28.41 and a two-hundred day simple moving average of $26.79. Pharvaris N.V. has a 12-month low of $15.46 and a 12-month high of $33.33. The stock has a market cap of $1.95 billion, a P/E ratio of -9.43 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, sell-side analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on PHVS shares. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Wolfe Research initiated coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Wedbush lifted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.18.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. General Atlantic L.P. lifted its position in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC lifted its position in Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after acquiring an additional 368,000 shares in the last quarter. venBio Partners LLC lifted its position in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. lifted its position in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP lifted its position in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.